MitoRx Therapeutics Limited Neil joins from Novo Nordisk and brings more than 20 years of experience in business development and strategic transactions Appointment strengthens MitoRx's business development capabilities as the Company advances MTRX31 towards the clinic for metabolically unhealthy obesity Harwell Oxford, UK – 3 November 2026: MitoRx Therapeutics ("MitoRx"), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, today announces the appointment of Neil Anderson, PhD as Chief Business Officer, effective immediately. Neil will join the senior management team and report to Jon Rees, PhD, Co-founder and Chief Executive Officer.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.